NMR spectroscopy of filtered serum of prostate cancer: A new frontier in metabolomics

被引:44
作者
Kumar, Deepak [1 ,2 ]
Gupta, Ashish [1 ]
Mandhani, Anil [3 ]
Sankhwar, Satya Narain [4 ]
机构
[1] Ctr Biomed Res, Dept Metabol, SGPGIMS Campus,Raebareli Rd, Lucknow 226014, Uttar Pradesh, India
[2] Uttar Pradesh Tech Univ, Lucknow, Uttar Pradesh, India
[3] Sanjay Gandhi Post Grad Inst Med Sci, Dept Urol, Lucknow, Uttar Pradesh, India
[4] King Georges Med Univ, Dept Urol, Lucknow 226003, Uttar Pradesh, India
关键词
NMR spectroscopy; serum; multivariate analysis; DFA; HUMAN SEMINAL FLUID; CITRATE; SARCOSINE; BIOMARKERS; TISSUE; URINE; RISK; OXIDATION; LACTATE; MARKERS;
D O I
10.1002/pros.23198
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUNDTo address the shortcomings of digital rectal examinations (DRE), serum prostate-specific antigen (PSA), and trans-rectal ultrasound (TRUS) for precise determination of prostate cancer (PC) and differentiation from benign prostatic hyperplasia (BPH), we applied H-1-nuclear magnetic resonance (NMR) spectroscopy as a surrogate tactic for probing and prediction of PC and BPH. METHODSThe study comprises 210 filtered sera from suspected PC, BPH, and a healthy subjects' cohort (HC). The filtered serum approach delineates to identify and quantify 52 metabolites using H-1 NMR spectroscopy. All subjects had undergone clinical evaluations (DRE, PSA, and TRUS) followed by biopsy for Gleason score, if needed. NMR-measured metabolites and clinical evaluation data were examined separately using linear multivariate discriminant function analysis (DFA) to probe the signature descriptors for each cohort. RESULTSDFA indicated that glycine, sarcosine, alanine, creatine, xanthine, and hypoxanthine were able to determine abnormal prostate (BPH+PC). DFA-based classification presented high precision (86.2% by NMR and 68.1% by clinical laboratory method) in discriminating HC from BPH+PC. DFA reveals that alanine, sarcosine, creatinine, glycine, and citrate were able to discriminate PC from BPH. DFA-based categorization exhibited high accuracy (88.3% by NMR and 75.2% by clinical laboratory method) to differentiate PC from BPH. (CONCLUSIONSH)-H-1 NMR-based metabolic profiling of filtered-serum sample appears to be assuring, swift, and least-invasive for probing and prediction of PC and BPH with its signature metabolic profile. This novel technique is not only on a par with histopathological evaluation of PC determination but is also comparable to liquid chromatography-based mass spectrometry to identify the metabolites. Prostate 76:1106-1119, 2016. (c) 2016 Wiley Periodicals, Inc.
引用
收藏
页码:1106 / 1119
页数:14
相关论文
共 50 条
[31]   High-throughput metabolomics enables biomarker discovery in prostate cancer [J].
Liang, Qun ;
Liu, Han ;
Xie, Li-xiang ;
Li, Xue ;
Zhang, Ai-Hua .
RSC ADVANCES, 2017, 7 (05) :2587-2593
[32]   Serum Colorectal Cancer Biomarkers Unraveled by NMR Metabolomics: Past, Present, and Future [J].
Salmeron, Ana M. ;
Tristan, Ana, I ;
Abreu, Ana C. ;
Fernandez, Ignacio .
ANALYTICAL CHEMISTRY, 2022, 94 (01) :417-430
[33]   New findings on urinary prostate cancer metabolome through combined GC-MS and1H NMR analytical platforms [J].
Lima, Ana Rita ;
Pinto, Joana ;
Barros-Silva, Daniela ;
Jeronimo, Carmen ;
Henrique, Rui ;
Bastos, Maria de Lourdes ;
Carvalho, Marcia ;
Pinho, Paula Guedes .
METABOLOMICS, 2020, 16 (06)
[34]   A primer to nutritional metabolomics by NMR spectroscopy and chemometrics [J].
Savorani, Francesco ;
Rasmussen, Morten Arendt ;
Mikkelsen, Mette Skau ;
Engelsen, Soren Balling .
FOOD RESEARCH INTERNATIONAL, 2013, 54 (01) :1131-1145
[35]   Response of Degarelix treatment in human prostate cancer monitored by HR-MAS 1H NMR spectroscopy [J].
Madhu, Basetti ;
Shaw, Greg L. ;
Warren, Anne Y. ;
Neal, David E. ;
Griffiths, John R. .
METABOLOMICS, 2016, 12 (07)
[36]   Fast targeted multidimensional NMR metabolomics of colorectal cancer [J].
Ludwig, C. ;
Ward, D. G. ;
Martin, A. ;
Viant, M. R. ;
Ismail, T. ;
Johnson, P. J. ;
Wakelam, M. J. O. ;
Guenther, U. L. .
MAGNETIC RESONANCE IN CHEMISTRY, 2009, 47 :S68-S73
[37]   Global serum metabolomics profiling of colorectal cancer [J].
Hashim, Nurul Azmir Amir ;
Ab-Rahim, Sharaniza ;
Suddin, Leny Suzana ;
Saman, Mohd Shahril Ahmad ;
Mazlan, Musalmah .
MOLECULAR AND CLINICAL ONCOLOGY, 2019, 11 (01) :3-14
[38]   Serum and Tissue Metabolomics of Head and Neck Cancer [J].
Yonezawa, Koichiro ;
Nishiumii, Shin ;
Kitamoto-Matsuda, Junko ;
Fujita, Takeshi ;
Morimoto, Koichi ;
Yamashita, Daisuke ;
Saito, Miki ;
Otsuki, Naoki ;
Irino, Yasuhiro ;
Shinohara, Masakazu ;
Yoshida, Masaru ;
Nibu, Ken-Ichi .
CANCER GENOMICS & PROTEOMICS, 2013, 10 (05) :233-238
[39]   Staging of colorectal cancer using serum metabolomics with 1HNMR Spectroscopy [J].
Vahabi, Farideh ;
Sadeghi, Sedigheh ;
Arjmand, Mohammad ;
Mirkhani, Fatemeh ;
Hosseini, Eshagh ;
Mehrabanfar, Mahsheed ;
Hajhosseini, Reza ;
Iravani, Ayda ;
Bayat, Parastou ;
Zamani, Zahra .
IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2017, 20 (07) :835-840
[40]   Discovery of serum biomarkers for diagnosis of tuberculosis by NMR metabolomics including cross-validation with a second cohort [J].
Conde, R. ;
Laires, R. ;
Goncalves, L. G. ;
Rizvi, A. ;
Barroso, C. ;
Villar, M. ;
Macedo, R. ;
Simoes, M. J. ;
Gaddam, S. ;
Lamosa, P. ;
Puchades-Carrasco, L. ;
Pineda-Lucena, A. ;
Patel, A. B. ;
Mande, S. C. ;
Banerjee, S. ;
Matzapetakis, M. ;
Coelho, A., V .
BIOMEDICAL JOURNAL, 2022, 45 (04) :654-664